Drug Trial Radar · NCT06670352
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Oct 12, 2024
Primary completion
Dec 20, 2025
Study completion May 15, 2026
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
Conditions
- IgA Nephropathy (IgAN)
Interventions
PlaceboDrug
QD or BID, 24-weeks fixed dose.
HSK39297 50mgBIDDrug
24-weeks fixed dose.
HSK39297 100mgBIDDrug
24-weeks fixed dose.
HSK39297 200mgQDDrug
24-weeks fixed dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ratio of 24-hour urine protein to creatinine (24h-UPCR) compared to baseline after 12 weeks of treatmentTime frame: From week 1 to week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.